Literature DB >> 20055898

Feasibility and challenges of independent research on drugs: the Italian medicines agency (AIFA) experience.

.   

Abstract

Key points * National Health Service (NHS) is becoming increasingly aware of the need to support independent research to answer some important questions for patient care in areas of scant commercial interest. * This article reports the main features and strategies of the independent research programme on drugs launched by the Italian Medicines Agency (AIFA) in 2005. * In the three bids launched between 2005 and 2007, a total of 151 studies have been approved for funding for a total of about 78 million Euro. * In this article we describe the Italian legislative framework under which the programme was launched, the types of research funded and discuss how the supported studies could contribute, in an international framework, to the knowledge needed on drug efficacy, effectiveness and safety.

Entities:  

Mesh:

Year:  2010        PMID: 20055898     DOI: 10.1111/j.1365-2362.2009.02226.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  15 in total

1.  Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

Authors:  Domenico Sansonno; Gianfranco Lauletta; Sabino Russi; Vincenza Conteduca; Loredana Sansonno; Franco Dammacco
Journal:  Oncologist       Date:  2012-02-14

2.  How legislation on decisional capacity can negatively affect the feasibility of clinical trials in patients with dementia.

Authors:  Francesca Galeotti; Nicola Vanacore; Sabina Gainotti; Fabio Izzicupo; Francesca Menniti-Ippolito; Carlo Petrini; Flavia Chiarotti; Rabih Chattat; Roberto Raschetti
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 3.  Can systematic reviews contribute to regulatory decisions?

Authors:  Corrado Barbui; Antonio Addis; Laura Amato; Giuseppe Traversa; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2017-01-07       Impact factor: 2.953

4.  Models for financing the regulation of pharmaceutical promotion.

Authors:  Joel Lexchin
Journal:  Global Health       Date:  2012-07-11       Impact factor: 4.185

5.  Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries.

Authors:  Markus Hartmann
Journal:  Trials       Date:  2012-04-29       Impact factor: 2.279

6.  Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews.

Authors:  Rita Banzi; Lorenzo Moja; Vanna Pistotti; Andrea Facchini; Alessandro Liberati
Journal:  Health Res Policy Syst       Date:  2011-06-24

7.  Financial disclosures of authors involved in spine research: an underestimated source of bias.

Authors:  Ronald H M A Bartels; Hans Delye; Jeroen Boogaarts
Journal:  Eur Spine J       Date:  2011-11-24       Impact factor: 3.134

8.  Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trials.

Authors:  Nicola Magrini; Giulio Formoso; Oreste Capelli; Emilio Maestri; Francesco Nonino; Barbara Paltrinieri; Cinzia Del Giovane; Claudio Voci; Lucia Magnano; Lisa Daya; Anna Maria Marata
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation.

Authors:  Anna V Zetterqvist; Juan Merlo; Shai Mulinari
Journal:  PLoS Med       Date:  2015-02-17       Impact factor: 11.069

10.  Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases.

Authors:  Giuseppe Traversa; Lucia Masiero; Luciano Sagliocca; Francesco Trotta
Journal:  Orphanet J Rare Dis       Date:  2016-04-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.